-
公开(公告)号：EP2326179A1
公开(公告)日：2011-06-01
申请号：EP09810478.9
申请日：2009-08-21
发明人： TEDESCO, Rossana
IPC分类号： A01N43/54
CPC分类号： C07D213/82
摘要： The invention described herein relates to certain pyrimidinedione N-substituted glycine derivatives of formula (I) which are antagonists of HIF prolyl hydroxylases and are useful for treating diseases benefiting from the inhibition of this enzyme, anemia being one example.
摘要翻译： 本文所述的发明涉及式（I）的某些嘧啶二酮N-取代的甘氨酸衍生物，它们是HIF脯氨酰羟化酶的拮抗剂并且可用于治疗受益于抑制该酶的疾病，贫血是一个实例。
-
公开(公告)号：EP2152310A2
公开(公告)日：2010-02-17
申请号：EP08780583.4
申请日：2008-04-30
发明人： BACHERT, Claus
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/244 , A61K31/56 , A61K39/3955 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/90 , A61K2300/00
摘要： The present invention relates generally to the methods for the treatment and diagnosis of conditions mediated by IL-5 and excess eosinophil production, and more specifically to mAbs, Fabs, chimeric and humanized antibodies. More particularly, methods are provided for reducing eosinophils in a human in need thereof, which method comprises administering to said human a composition comprising at least one anti-IL-5 antibody, wherein at least one anti-IL-5 antibody provides a mean maximum plasma concentration of said anti-IL-5 antibody of at least about 1.03 ± 0.21 µg/mL, an Area Under the Curve value of at least about 15.5 ± 2.7 µg/day/mL and a serum half-life of about 16.2 ± 2.1 days to about 21.7 ± 2.8 days.
摘要翻译： 本发明涉及在人中治疗鼻息肉病的方法，其包括向有此需要的所述人施用有效量的包含至少一种抗IL-5抗体的组合物的步骤，其中所述抗体包含重链和 一条轻链。
-
公开(公告)号：EP1924572B1
公开(公告)日：2009-12-30
申请号：EP06813938.5
申请日：2006-08-28
发明人： HORNBERGER, Keith , CHEUNG, Mui , POBANZ, Mark, Andrew , EMMITTE, Kyle, Allen , KUNTZ, Kevin, Wayne , BADIANG, Jennifer, Gabriel
IPC分类号： C07D333/40 , C07D409/04
CPC分类号： C07D333/40 , C07D409/04
摘要： The present invention provides a process for preparing benzimidazole thiophene compounds of formula I. Intermediates used in the process are also claimed.
-
公开(公告)号：EP1490047B1
公开(公告)日：2009-12-30
申请号：EP03719457.8
申请日：2003-03-26
发明人： THOMPSON, Scott, K. , FRAZEE, James, S. , KALLANDER, Lara, S. , MA, Chum , MARINO, Joseph, P. , NEEB, Michael, J. , BHAT, Ajita
IPC分类号： A61K31/34 , A61K31/38 , A61K31/40 , C07D209/14 , C07D209/16 , C07D307/81 , C07D333/58 , C07D407/12 , A61P9/00
CPC分类号： C07D307/81 , C07D307/79 , C07D407/12
摘要： Disclosed is a compound of having the formula: (I) pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.
-
公开(公告)号：EP2121637A1
公开(公告)日：2009-11-25
申请号：EP08728247.1
申请日：2008-01-25
发明人： AXTEN, Jeffrey, Michael , BRYAN, Deborah, L. , DREWRY, David, Harold , FAITG, Thomas, H. , GALLAGHER, Thimothy, Francis , JOHNSON, Neil, W. , KASPAREC, Jiri , RALPH, Jeffrey, M. , SILVA, Domingos, J.
IPC分类号： C07D241/04 , A61K31/496 , A61P35/00
CPC分类号： C07D403/12 , C07D241/20 , C07D413/12
摘要： The present invention relates to a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof; where R1, R2, R3, R4, r and s are as previously defined. Compounds of the present invention are useful in the treatment of diseases associated with Aurora kinase activity such as cancer.
-
公开(公告)号：EP2120898A1
公开(公告)日：2009-11-25
申请号：EP07855230.4
申请日：2007-12-18
IPC分类号： A61K31/00
CPC分类号： C07C229/34 , C07C323/32 , C07C2602/08 , C07D333/20
摘要： Novel calcilytic compounds, pharmaceutical compositions, methods of synthesis and methods of using them are provided.
摘要翻译： 提供了新的钙溶解化合物，药物组合物，合成方法和使用它们的方法。
-
公开(公告)号：EP2117523A1
公开(公告)日：2009-11-18
申请号：EP08729249.6
申请日：2008-02-07
发明人： SEEFELD, Mark, Andrew , ROUSE, Meagan, B. , HEERDING, Dirk, A. , PEACE, Simon , YAMASHITA, Dennis, S. , MCNULTY, Kenneth, C.
IPC分类号： A61K31/12
CPC分类号： A61K31/4155 , A61K9/0019 , A61K9/0053 , A61K9/20 , A61K9/48 , A61K31/12 , A61K31/4178 , A61K31/4192 , A61K31/4196 , A61K31/4439 , A61K45/06 , C07D403/04 , C07D405/04 , C07D405/12 , C07D409/04 , C07D409/12 , C07D409/14
摘要： Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
-
8.发明公开
公开(公告)号：EP2081894A1
公开(公告)日：2009-07-29
申请号：EP07841701.1
申请日：2007-08-31
发明人： SPEARING, Paul Kenneth , LAMBERT, Millard Hurst , RAY, John A , LAUDEMAN, Christopher P , SZEWCZYK, Jerzy R , BANKER, Pierette , OPLINGER, Jeffrey, Alan
IPC分类号： C07D209/42 , C07D401/04 , C07D403/12 , C07D407/04 , C07D409/12 , A61K31/404 , A61K31/4439 , A61K31/4166 , A61K31/496 , A61K31/5377 , A61P3/00
CPC分类号： C07D209/42 , C07D401/04 , C07D401/12 , C07D403/12 , C07D405/04 , C07D409/12 , C07D413/10 , C07D413/12 , C07D417/10
摘要： The present invention relates to certain indole derivatives that are modulators of PPAR, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine.
-
公开(公告)号：EP2079307A2
公开(公告)日：2009-07-22
申请号：EP07863446.6
申请日：2007-10-23
发明人： BASS, Jonathan York III , DEATON, David Norman , CARAVELLA, Justin , MCFADYEN, Robert Blount , NAVAS, Frank Iii , SPEARING, Paul Kenneth
CPC分类号： C07D413/14 , C07D413/12
摘要： The present invention provides novel substituted isoxazole compounds, pharmaceutical compositions, therapeutic uses and processes for preparing the same.
摘要翻译： 本发明提供了新的取代的异恶唑化合物，药物组合物，治疗用途及其制备方法。
-
公开(公告)号：EP2069387A1
公开(公告)日：2009-06-17
申请号：EP07875099.9
申请日：2007-06-13
IPC分类号： C07K1/22
CPC分类号： C07K1/20 , C07K1/18 , C07K16/065
摘要： This invention relates to the purification of monoclonal antibodies from mammalian cell culture fluid utilizing sequential, orthogonal chromatography and filtration techniques resulting in material of high purity and quality that is suitable for human administration. The method involves capturing an IgG product using immobilized protein A affinity chromatography, followed by at least one ion exchange technique prior to adsorbing the IgG to hydroxyapatite and selectively eluting the product in a single isocratic step to achieve purification from impurities and simultaneously reducing multiple types of impurities including but not limited to IgG aggregates, residual protein A, non-IgG proteins, host cell proteins, viral particles, and DNA.
-
-
-
-
-
-
-
-
-
搜索结果
2675 条记录 (耗时 0.035 秒)
